Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

Conditions

• T-Cell Large Granular Lymphocyte Leukemia

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Ruxolitinib — DRUG
  Given PO

Study Details

This phase II trial tests whether ruxolitinib works to shrink tumors in patients with T-cell large granular lymphocyte leukemia. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Key Dates

Start date

May 3, 2023

Status verified

Feb 2026

Primary completion

Jul 31, 2026

Completion

Jul 31, 2026

Study Design

Enrollment

30 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Treatment (ruxolitinib)
  Patients receive ruxolitinib PO BID on days 1-28. Cycles repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity. Patients who achieve a response (CR or PR) may receive an additional 12 months of ruxolitinib, for a maximum of 24 months.

Primary Outcome Measure

Overall response rate (ORR) [ Time Frame: Up to 12 months ]

Central Contacts

• The Ohio State University Comprehensive Cancer Center
  800-293-5066
  [email protected]
• Lily Yang
  614-293-6191
  [email protected]

Locations (3)

Find similar trials in Boston, MA

Related Studies

• A Study of Ruxolitinib and Duvelisib in People With Lymphoma
  PHASE1 · Recruiting · Memorial Sloan Kettering Cancer Center · Miami, Florida